Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis

INTRODUCTION: Antifibrinolytic agents are commonly used during cardiac surgery to minimize bleeding. Because of safety concerns, aprotinin was withdrawn from the market in 2007. Since then, tranexamic acid (TXA) has become the antifibrinolytic treatment of choice in many heart centers. The safety pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sander, Michael, Spies, Claudia D, Martiny, Viktoria, Rosenthal, Christoph, Wernecke, Klaus-Dieter, von Heymann, Christian
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945131/
https://www.ncbi.nlm.nih.gov/pubmed/20682059
http://dx.doi.org/10.1186/cc9216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945131/
https://www.ncbi.nlm.nih.gov/pubmed/20682059
http://dx.doi.org/10.1186/cc9216

Ejemplares similares